CNTG vs. PMD, BGLC, DMTK, OPGN, XGN, COCP, VBIV, TLIS, TRAW, and ONMD
Should you be buying Centogene stock or one of its competitors? The main competitors of Centogene include Psychemedics (PMD), BioNexus Gene Lab (BGLC), DermTech (DMTK), OpGen (OPGN), Exagen (XGN), Cocrystal Pharma (COCP), VBI Vaccines (VBIV), Talis Biomedical (TLIS), Traws Pharma (TRAW), and OneMedNet (ONMD). These companies are all part of the "medical" sector.
Centogene (NASDAQ:CNTG) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
In the previous week, Centogene had 2 more articles in the media than Psychemedics. MarketBeat recorded 2 mentions for Centogene and 0 mentions for Psychemedics. Psychemedics' average media sentiment score of 0.00 beat Centogene's score of -0.01 indicating that Psychemedics is being referred to more favorably in the news media.
Centogene has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500. Comparatively, Psychemedics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.
Psychemedics has lower revenue, but higher earnings than Centogene.
9.9% of Centogene shares are held by institutional investors. Comparatively, 32.1% of Psychemedics shares are held by institutional investors. 1.9% of Centogene shares are held by insiders. Comparatively, 24.0% of Psychemedics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Centogene has a net margin of 0.00% compared to Psychemedics' net margin of -18.39%. Centogene's return on equity of 0.00% beat Psychemedics' return on equity.
Centogene currently has a consensus target price of $1.50, indicating a potential upside of 225.38%. Given Centogene's higher possible upside, analysts clearly believe Centogene is more favorable than Psychemedics.
Psychemedics received 102 more outperform votes than Centogene when rated by MarketBeat users. Likewise, 74.35% of users gave Psychemedics an outperform vote while only 64.52% of users gave Centogene an outperform vote.
Summary
Psychemedics beats Centogene on 7 of the 13 factors compared between the two stocks.
Get Centogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centogene Competitors List
Related Companies and Tools
